Extended Data Fig. 1: Patient flow diagram.
From: Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Reasons for ineligibility: 60 patients were ineligible because they did not meet at least one inclusion and/or exclusion criterion. Most common causes of ineligibility were not meeting the inclusion criterion regarding the provision of a biopsy sample (n = 15); exclusion criterion regarding absence of active central nervous system metastases (n = 11); inclusion criteria regarding histologically confirmed diagnosis of advanced unresectable stage III or metastatic stage IV melanoma (n = 8); inclusion criterion regarding provision of informed consent (n = 7); inclusion criterion regarding BRAF mutation status (n = 5); inclusion criterion regarding adequate organ function (n = 4). Detailed inclusion and exclusion criteria are provided in the study protocol. BID, twice daily; QD, once daily; Q3W, every 3 weeks.
